Delivery Order SPE2DB20D1004-SPE2DB24FNCPR
Award Date
9/18/24
Potential Completion Date
9/19/24
Potential Value
$13K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $31,939.92, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This federal contract award, valued at $2,942.32, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, with a performance period ending on December 5, 2024. The contract is a Delivery Order and is priced as a Firm Fixed Price. This award is not associated with a set-aside program. The contract is part...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $15,985.25 contract is a firm fixed-price delivery order for HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product. The award has an ultimate completion date of November 21, 2024. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $97,545.40, is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. This is a firm fixed-price delivery order contract with a completion date of February 28, 2025. The contract was awarded on February 27, 2025 and does not have a set-aside designation, indicating open...
This federal contract award, valued at $3,154.56, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, with a completion date of May 2, 2024. The award is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA, valued up to $999,999,999.00 through December 2025. This single-award IDC serves...
This federal contract award, valued at $71,491.46, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, with a completion date of December 19, 2024. The contract is a Delivery Order with a Firm Fixed Price pricing type. This award does not have a set-aside designation, indicating open competition....
This federal contract award, valued at $12,102.80, was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a medical product, with a completion date of January 29, 2024. This award is not designated as a set-aside contract. AmerisourceBergen Drug Corp is a subsidiary of Cencora, Inc., the parent company. The contract is a...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product, with a ceiling value of $2,039.05 and a completion date of November 20, 2024. This is a delivery order contract with a firm fixed price pricing type. The award is not associated with a set-aside program. Amerisourcebergen Drug...
This is a federal contract award made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product, with a ceiling value of $1,971.60 and a completion date of October 22, 2024. This award was made as a delivery order under an Indefinite Delivery Contract (IDC) the vendor holds with the DLA Troop Support Medical, valued at...
This federal contract award, valued at $81,562.00, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. The contract has a Firm Fixed Price pricing type and an ultimate completion date of December 11, 2024. This award is not associated with a set-aside designation. Amerisourcebergen Drug Corp is a...